Elliot Wilbur
Stock Analyst at Raymond James
(1.62)
# 1,452
Out of 4,641 analysts
58
Total ratings
32.65%
Success rate
-1.37%
Average return
Main Sectors:
Stocks Rated by Elliot Wilbur
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Maintains: Outperform | $81 → $83 | $59.04 | +40.58% | 12 | Sep 18, 2024 | |
| SLGL Sol-Gel Technologies | Downgrades: Outperform | $6 → $4 | $0.67 | +497.01% | 8 | Aug 19, 2024 | |
| ADMA ADMA Biologics | Maintains: Strong Buy | $8 → $10 | $15.69 | -36.27% | 6 | May 10, 2024 | |
| OGN Organon & Co. | Initiates: Outperform | $33 | $17.21 | +91.75% | 1 | Mar 16, 2023 | |
| PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $25.39 | +69.36% | 6 | Mar 6, 2023 | |
| PETQ PetIQ | Maintains: Outperform | $21 → $16 | $30.99 | -48.37% | 5 | Oct 25, 2022 | |
| PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $3.29 | +3,547.42% | 3 | Sep 6, 2022 | |
| VTRS Viatris | Downgrades: Market Perform | n/a | $11.55 | - | 3 | Mar 1, 2022 | |
| TEVA Teva Pharmaceutical | Downgrades: Market Perform | n/a | $18.41 | - | 4 | Oct 28, 2021 | |
| ZTS Zoetis | Downgrades: Market Perform | n/a | $188.99 | - | 4 | Jul 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $12.51 | - | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $5.95 | - | 2 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $49.83 | - | 3 | Nov 9, 2017 |
ANI Pharmaceuticals
Sep 18, 2024
Maintains: Outperform
Price Target: $81 → $83
Current: $59.04
Upside: +40.58%
Sol-Gel Technologies
Aug 19, 2024
Downgrades: Outperform
Price Target: $6 → $4
Current: $0.67
Upside: +497.01%
ADMA Biologics
May 10, 2024
Maintains: Strong Buy
Price Target: $8 → $10
Current: $15.69
Upside: -36.27%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $17.21
Upside: +91.75%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $25.39
Upside: +69.36%
PetIQ
Oct 25, 2022
Maintains: Outperform
Price Target: $21 → $16
Current: $30.99
Upside: -48.37%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $3.29
Upside: +3,547.42%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $11.55
Upside: -
Teva Pharmaceutical
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $18.41
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $188.99
Upside: -
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $12.51
Upside: -
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $5.95
Upside: -
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $49.83
Upside: -